Search For "subject expert committee"
Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets
Updated : 1 year, 2 months ago IST
Raichur (Karnataka) [India], March 12: Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets
Read More
Expert committee approves Bharat Biotech International's proposal to condu
Updated : 2 years ago IST
The Subject Expert Committee (SEC) under the Central Drug Standard Control Organisation (CDSCO) has approved vaccine major Bharat Biotech International's proposal to conduct the Phase II clinical trial of Mycobacterium Tuberculosis (Live Attenuated) Vaccine to assess the safety and immunogen
Read More
Govt expert panel recommends JV firm's vaccine for pneumococcal infections
Updated : 3 years, 4 months ago IST
PCV15 vaccine was developed by Tergene Biotech and manufactured at Auro Vaccines, which is a wholly-owned subsidiary of Aurobindo Pharma with capabilities in vaccines development and manufacturing. Aurobindo Pharma holds 80 per cent stake in the joint venture company, Tergene Biotech.
Read More
DCGI's subject expert committee to hold discussion on 'Five Arms' intranas
Updated : 3 years, 6 months ago IST
DCGI has already given emergency use authorization (EUA) to BBIL for the intranasal vaccine. BBIL had in September this year applied for DCGI's approval for market authorization of its "Five Arms" intranasal heterologous booster dose, and it has now announced that iNCOVACC (BBV154) has re
Read More
Biological E announces CDSCO's recommendation of its 14-Valent Pneumococca
Updated : 3 years, 8 months ago IST
Hyderabad (Telangana) [India] September 1 (ANI): Hyderabad-based vaccines manufacturer Biological E Limited announced on Thursday that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) reviewed and approved the Phase III infants clinical trial data
Read More
India's first mRNA COVID-19 vaccine to get Emergency Use Authorisation soo
Updated : 3 years, 11 months ago IST
New Delhi [India], June 28 (ANI): The Subject Expert Committee (SEC) in a meeting held on Friday recommended Emergency Use Authorisation (EUA) for India's first mRNA COVID-19 vaccine, sources told ANI on Tuesday.
Read More
SEC recommends India's first indigenously developed vaccine against cervic
Updated : 3 years, 11 months ago IST
New Delhi [India], June 15 (ANI): The subject expert committee meeting that was scheduled today to discuss Serum Institute of India's (SII) indigenously developed Quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, has recommended regular market authorisation for above
Read More
SEC to discuss India's first indigenously developed vaccine against cervic
Updated : 3 years, 11 months ago IST
New Delhi [India] June 15 (ANI): The first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer by the Serum Institute of India (SII) will be discussed by the Subject expert committee on Wednesday.
Read More
SEC seeks more data from Serum Institute over COVID vaccine Covovax for 7-
Updated : 4 years ago IST
New Delhi [India], April 30 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee on Friday sought more data from Pune based Serum Institute of India (SII) on the Covovax vaccine for the age group of 7-12 years.
Read More
Bharat Biotech asked to provide more data on COVID-19 vaccine Covaxin for
Updated : 4 years, 1 month ago IST
New Delhi [India], April 22 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said.
Read More
Subject Expert Panel recommends Corbevax COVID-19 vaccines for children ag
Updated : 4 years, 1 month ago IST
New Delhi [India], April 21 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has recommended restricted emergency use of Biological E's Corbevax COVID-19 vaccine for children aged 5-11, said sources on Thursday.
Read More
Expert panel of DCGI holds meet to discuss recommendations to use COVID-19
Updated : 4 years, 1 month ago IST
New Delhi [India], April 21 (ANI): The meeting of the Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is underway to discuss recommendations on restricted emergency use of Bharat Biotech's Covaxin and Biological E's Corbevax COVID-19 vaccine for children aged
Read More